Oncotelic Therapeutics Expands IP Shield Across key Markets, Fortifying OT-101 and CNS Tech

Oncotelic Therapeutics US6283411097

Oncotelic Therapeutics is strengthening its position in neuroscience by securing new patent protections in Australia, China, and Germany. The legal wins reinforce the commercial pathway for the OT-101 drug candidate and for device concepts tailored to CNS delivery, underscoring the company?s strategy to establish integrated drug and medtech solutions for central nervous system treatment.

• Australia: OT-101 receives a patent grant for use in Parkinson?s disease, including associated sleep disturbances.
• China & Germany: Utility models granted for a device enabling continuous intracranial infusion.
• Strategic objective: Develop an integrated platform combining OT-101 with specialized medical hardware.

Parkinson?s focus and medtech integration

The newly granted rights are designed to form a multi-layered barrier around OT-101. In Australia, patent claims cover the application of OT-101 for Parkinson?s disease, encompassing treatment of related sleep symptoms and direct administration into the brain or spinal canal.

Concurrently, protection for hardware approaches has been extended in key markets. China issued a utility model for a device enabling continuous intracranial infusion, while Germany granted a corresponding protection that runs through 2033. These devices are central to delivering pharmaceutical agents directly into the CNS.

Valuation of the pipeline and strategic equity

The IP expansion comes on the heels of a recent operational update. The company cited an independent assessment of its joint venture GMP Bio, valuing the projects at roughly US$1.7 billion, with Oncotelic holding a 45 percent stake in the consortium.

In parallel, notable clinical milestones were announced: a Phase-1 study combining OT-101 with IL-2 has reached its completion, and human testing has begun for Sapu-003, a candidate derived from Oncotelic?s own Nanomedicine platform. The company will need to keep pace with patent protection developments as clinical progress continues.

Outlook at BIO-Europe Spring

Attention now shifts to BIO-Europe Spring, scheduled for March 23?25, where Oncotelic plans to present clinical data for OT-101 and the Sapu-003 candidate. The presentations are expected to offer deeper insights into the clinical trajectory of these programs, now supported by an expanded global patent shield.